RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Equar Taka to Humans

This is a "connection" page, showing publications Equar Taka has written about Humans.
Connection Strength

0.149
  1. Taka E, Errahali YJ, Abonyo BO, Bauer DM, Heiman AS. Post-transcriptional silencing of CCR3 downregulates IL-4 stimulated release of eotaxin-3 (CCL26) and other CCR3 ligands in alveolar type II cells. Cytokine. 2008 Dec; 44(3):342-51.
    View in: PubMed
    Score: 0.015
  2. Ferguson DT, Taka E, Messeha S, Flores-Rozas H, Reed SL, Redmond BV, Soliman KFA, Kanga KJW, Darling-Reed SF. The Garlic Compound, Diallyl Trisulfide, Attenuates Benzo[a]Pyrene-Induced Precancerous Effect through Its Antioxidant Effect, AhR Inhibition, and Increased DNA Repair in Human Breast Epithelial Cells. Nutrients. 2024 Jan 19; 16(2).
    View in: PubMed
    Score: 0.011
  3. Ferguson DT, Taka E, Tilghman SL, Womble T, Redmond BV, Gedeon S, Flores-Rozas H, Reed SL, Soliman KFA, Kanga KJW, Darling-Reed SF. The Anticancer Effects of the Garlic Organosulfide Diallyl Trisulfide through the Attenuation of B[a]P-Induced Oxidative Stress, AhR Expression, and DNA Damage in Human Premalignant Breast Epithelial (MCF-10AT1) Cells. Int J Mol Sci. 2024 Jan 11; 25(2).
    View in: PubMed
    Score: 0.011
  4. Adinew GM, Messeha S, Taka E, Mochona B, Redda KK, Soliman KFA. Thymoquinone Inhibition of Chemokines in TNF-a-Induced Inflammatory and Metastatic Effects in Triple-Negative Breast Cancer Cells. Int J Mol Sci. 2023 Jun 08; 24(12).
    View in: PubMed
    Score: 0.011
  5. Adinew GM, Messeha S, Taka E, Ahmed SA, Soliman KFA. The Role of Apoptotic Genes and Protein-Protein Interactions in Triple-negative Breast Cancer. Cancer Genomics Proteomics. 2023 May-Jun; 20(3):247-272.
    View in: PubMed
    Score: 0.011
  6. Adinew GM, Messeha SS, Taka E, Badisa RB, Soliman KFA. Anticancer Effects of Thymoquinone through the Antioxidant Activity, Upregulation of Nrf2, and Downregulation of PD-L1 in Triple-Negative Breast Cancer Cells. Nutrients. 2022 Nov 13; 14(22).
    View in: PubMed
    Score: 0.010
  7. Adinew GM, Messeha SS, Taka E, Badisa RB, Antonie LM, Soliman KFA. Thymoquinone Alterations of the Apoptotic Gene Expressions and Cell Cycle Arrest in Genetically Distinct Triple-Negative Breast Cancer Cells. Nutrients. 2022 May 19; 14(10).
    View in: PubMed
    Score: 0.010
  8. Adinew G, Messeha SS, Badisa R, Taka E, Soliman KFA. Thymoquinone Anticancer Effects Through the Upregulation of NRF2 and the Downregulation of PD-L1 in MDA-MB-231 Triple-Negative Breast Cancer Cells. FASEB J. 2022 05; 36 Suppl 1.
    View in: PubMed
    Score: 0.010
  9. Payne A, Nahashon S, Taka E, Adinew GM, Soliman KFA. Epigallocatechin-3-Gallate (EGCG): New Therapeutic Perspectives for Neuroprotection, Aging, and Neuroinflammation for the Modern Age. Biomolecules. 2022 02 25; 12(3).
    View in: PubMed
    Score: 0.010
  10. Adinew GM, Taka E, Mochona B, Badisa RB, Mazzio EA, Elhag R, Soliman KFA. Therapeutic Potential of Thymoquinone in Triple-Negative Breast Cancer Prevention and Progression through the Modulation of the Tumor Microenvironment. Nutrients. 2021 Dec 25; 14(1).
    View in: PubMed
    Score: 0.010
  11. Adinew GM, Taka E, Mendonca P, Messeha SS, Soliman KFA. The Anticancer Effects of Flavonoids through miRNAs Modulations in Triple-Negative Breast Cancer. Nutrients. 2021 Apr 07; 13(4).
    View in: PubMed
    Score: 0.009
  12. Mazzio EA, Li N, Bauer D, Mendonca P, Taka E, Darb M, Thomas L, Williams H, Soliman KF. Natural product HTP screening for antibacterial (E.coli 0157:H7) and anti-inflammatory agents in (LPS from E. coli O111:B4) activated macrophages and microglial cells; focus on sepsis. BMC Complement Altern Med. 2016 Nov 15; 16(1):467.
    View in: PubMed
    Score: 0.007
  13. Green JE, Cooperwood JS, Taka E, Soliman KF, Goodman CB, Reams RR. Comparative proteomic analysis reveals growth inhibition by 3-N-alkyloxyestradiol derivative (SERM) in prostate cancer cells. Cancer Genomics Proteomics. 2014 Jul-Aug; 11(4):195-200.
    View in: PubMed
    Score: 0.006
  14. Bauer D, Mazzio E, Soliman KF, Taka E, Oriaku E, Womble T, Darling-Reed S. Diallyl disulfide inhibits TNFa-induced CCL2 release by MDA-MB-231 cells. Anticancer Res. 2014 Jun; 34(6):2763-70.
    View in: PubMed
    Score: 0.006
  15. Nkrumah-Elie YM, Reuben JS, Hudson AM, Taka E, Badisa R, Ardley T, Israel B, Sadrud-Din SY, Oriaku ET, Darling-Reed SF. The attenuation of early benzo(a)pyrene-induced carcinogenic insults by diallyl disulfide (DADS) in MCF-10A cells. Nutr Cancer. 2012; 64(7):1112-21.
    View in: PubMed
    Score: 0.005
  16. Nkrumah-Elie YM, Reuben JS, Hudson A, Taka E, Badisa R, Ardley T, Israel B, Sadrud-Din SY, Oriaku E, Darling-Reed SF. Diallyl trisulfide as an inhibitor of benzo(a)pyrene-induced precancerous carcinogenesis in MCF-10A cells. Food Chem Toxicol. 2012 Jul; 50(7):2524-30.
    View in: PubMed
    Score: 0.005
  17. Errahali YJ, Taka E, Abonyo BO, Heiman AS. CCL26-targeted siRNA treatment of alveolar type II cells decreases expression of CCR3-binding chemokines and reduces eosinophil migration: implications in asthma therapy. J Interferon Cytokine Res. 2009 Apr; 29(4):227-39.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support